EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Efficacy and safety of denosumab administered at 6-monthly versus 9-monthly intervals in postmenopausal osteoporosis: Protocol for a randomized, open-label, blinded endpoint clinical trial

Ranvijay Singh, Rimesh Pal, Sanjay Kumar Bhadada, Pinaki Dutta, Urmila Yadav, Richa Rattan, Naresh Sachdeva, Snigdha Kumari, Tulika Singh

Therapeutic Advances in Endocrinology and Metabolism · 2026-10 · 19

DOI: 10.1177/20420188261504166 ↗
AbstractBibliografische Angaben

Abstract

Background Denosumab is widely used for postmenopausal osteoporosis and is conventionally administered at 6-month intervals. However, pharmacodynamic and pharmacokinetic evidence suggests that suppression of bone turnover may persist beyond this duration. In a prior prospective study from our group, bone turnover marker-guided delayed dosing was not associated with early skeletal harm. Whether a longer fixed dosing interval can maintain skeletal efficacy while reducing treatment burden remains uncertain. Objectives To compare the efficacy and safety of denosumab administered at fixed 6-monthly versus 9-monthly intervals in postmenopausal women with osteoporosis. Design Prospective, randomized, open-label, blinded endpoint (PROBE) clinical trial. Methods Postmenopausal women aged ≥50 years with DXA-defined osteoporosis and/or prior fragility fracture will be randomized (1:1) to receive denosumab 60 mg subcutaneously every 6 months or every 9 months for 18 months (four vs. three doses), along with calcium and cholecalciferol supplementation. Participants will be followed for an additional 12 months after treatment discontinuation, with predefined criteria for rescue therapy using zoledronic acid. The primary endpoint is percent change in areal bone mineral density at the lumbar spine at 24 months. Secondary outcomes include incident fragility fractures, changes in trabecular bone score, HR-pQCT-derived microarchitecture and bone strength, longitudinal changes in bone turnover markers, and requirement for rescue therapy. Safety outcomes include hypocalcemia, osteonecrosis of the jaw, atypical femoral fractures, incident vertebral fractures during the extended-interval treatment period, and post-discontinuation skeletal events. Ethics The study has received institutional ethics approval, and written informed consent will be obtained from all participants. Discussion This trial is designed to provide the first randomized evidence evaluating whether a fixed extended dosing interval of denosumab can preserve skeletal efficacy. The findings are expected to inform optimization of dosing strategies, with potential implications for treatment burden and cost. Registration Prospectively registered in Clinical Trial Registry of India (CTRI/2025/12/099664) dated 22-12-2025.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →